{"filings":[{"id":668317,"accession_number":"0001628280-26-038109","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-05-26T20:26:14+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Medifast appoints Nicholas Johnson as CEO; Dan Chard becomes non-executive Chairman","event_type":"leadership","confidence":"high","bullets":["Nicholas Johnson, 46, becomes CEO effective June 1, 2026; Dan Chard transitions to non-executive Chairman.","Johnson's compensation: $600K base salary, target bonus 100% of base, LTI target 250% of base (69% increase vs. prior role).","Stockholders approved Amended 2012 Share Incentive Plan, increasing authorized shares by 250,000.","All seven director nominees elected; say-on-pay and auditor ratification passed.","Johnson joined Medifast in 2018, most recently as President; prior senior roles at Nu Skin Enterprises."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99657,"accession_number":"0001628280-26-029812","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q1 revenue $76M, down 34% YoY; net loss $2.1M; guides Q2 revenue $60-80M","event_type":"earnings","confidence":"high","bullets":["Revenue fell 34.3% to $76.0M; net loss widened to $2.1M ($0.19 EPS) from $0.8M loss.","Active earning coaches dropped 44.9% to 14,000; rev per coach up 19.2% to $5,432.","Gross margin 68.1% vs 72.8% a year ago; operating loss $3.3M vs $1.3M.","Outlook: Q2 rev $60-80M, EPS loss $0.50-$1.00; FY rev $270-300M, EPS loss $1.55-$2.75.","Cash $168.9M, no debt; expects active earning coaches to continue declining in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":76044000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115800,"accession_number":"0001628280-26-019983","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Medifast Enters Cooperation Agreement with Steamboat Capital, Nominates Two Directors, CEO to Step Down June 1, 2026","event_type":"leadership","confidence":"high","bullets":["Medifast (MED) entered a Cooperation Agreement with Steamboat Capital Partners (beneficial owner >5%) on March 19, 2026.","Medifast will nominate Steamboat designees Parsa Kiai and Jeff Rose as independent directors at the 2026 annual meeting on May 19, 2026.","Existing directors Jeffrey Brown and Michael Hoer will not stand for reelection at the 2026 annual meeting.","CEO Dan Chard will step down on June 1, 2026, remaining Chairman; President Nicholas Johnson to succeed as CEO.","Steamboat agreed to customary standstill and voting provisions through the 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115799,"accession_number":"0001628280-26-008641","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q4 revenue falls 37% to $75.1M; net loss $18.1M, guides FY26 rev $270-300M","event_type":"earnings","confidence":"high","bullets":["Revenue $75.1M, down 36.9% YoY; active earning coaches down 40.6% to 16,100.","Net loss $18.1M ($1.65 EPS) includes $12.1M non-cash tax valuation allowance ($1.10/sh).","Full year 2025 revenue $385.8M (-36% YoY); net loss $18.7M (-$1.70 EPS).","Guides Q1 2026 rev $65-80M, loss $0.15-$0.70/sh; FY26 rev $270-300M, loss $1.55-$2.75/sh."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":385788000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115798,"accession_number":"0001628280-26-000235","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Medifast CBOO Tyree departs Dec 31; COO Johnson promoted to President; CEO Chard to non-exec Chairman June 1, 2026","event_type":"leadership","confidence":"high","bullets":["Anthony Tyree (CBOO) departs Dec 31, 2025; receives $706,984 severance (salary + target bonus).","Nicholas Johnson promoted from Chief Field Operations Officer to President, effective Jan 5, 2026.","CEO Daniel Chard to transition to non-executive Chairman effective June 1, 2026; salary cut from $1M to $800K.","Chard's target bonus reduced from 115% to 100% and LTI from $4.6M to $2.4M until transition.","CFO James Maloney assumes leadership of supply chain function."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132220,"accession_number":"0001628280-25-048251","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q3 revenue down 36% to $89.4M; net loss $2.3M; coaches drop 35%","event_type":"earnings","confidence":"high","bullets":["Revenue $89.4M vs $140.2M YoY; net loss $0.21 per diluted share vs $0.10 income.","Active earning OPTAVIA coaches fell to 19,500 from 30,000, due to GLP-1 competition.","Gross margin 69.5% vs 75.4% on fixed-cost de-leverage and $180 basis pts for product reformulation.","Q4 2025 guidance: revenue $65M–$80M; diluted loss per share $0.70–$1.25.","Cash & investments $173.5M; no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":310692000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148787,"accession_number":"0000910329-25-000015","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q2 revenue falls 37.4% to $105.6M; active coaches down 33%; Q3 guidance weak","event_type":"earnings","confidence":"high","bullets":["Revenue $105.6M, down 37.4% YoY; active OPTA VIA coaches 22,800 (-32.7% YoY); diluted EPS $0.22 (includes $2.0M net LifeMD gain).","Net income $2.5M vs. loss $8.2M a year ago; operating loss improved to $1.1M from $7.9M.","Cash and investments $162.7M, no debt; LifeMD stake sold during quarter.","Q3 2025 guidance: revenue $70M-$90M; diluted EPS range ($0.60) to $0.00.","Management cites ongoing client acquisition challenges and GLP-1 competition."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":221283000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167672,"accession_number":"0001628280-25-032457","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Medifast stockholders approve 550k share increase to 2012 incentive plan and re-elect directors","event_type":"other","confidence":"high","bullets":["Stockholders approved Amended 2012 Plan adding 550,000 shares to the pool, totaling ~1,175,000 shares available.","All seven director nominees re-elected: Brown, Chard, Geary, Hoer, Schlackman, Thomas, Xian.","Advisory vote on executive compensation passed 3.59M for vs 2.48M against (41% opposed).","Ratification of RSM US LLP as auditor for FY2025 passed with 8.23M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167671,"accession_number":"0001628280-25-020336","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q1 2025: revenue down 34% to $115.7M, net loss $0.8M; Q2 guidance weak","event_type":"earnings","confidence":"high","bullets":["Revenue fell 33.8% to $115.7M; active earning coaches down 32.8% to 25,400.","Net loss of $0.8M vs. net income of $8.3M a year ago; diluted EPS -$0.07.","Gross margin held at 72.8%; operating loss $1.3M vs. operating income $7.9M.","Q2 2025 revenue guidance $85M-$105M; loss per share $0.00-$0.55.","Cash, equivalents, and investments $164.6M; no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":115728000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184957,"accession_number":"0001628280-25-006036","cik":910329,"company_name":"MEDIFAST INC","ticker":"MED","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medifast Q4 revenue down 38% to $119M; EPS $0.07; guides Q1 loss","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $119M (-37.7% YoY); active earning coaches 27,100 (-34.1% YoY).","Net income $0.8M ($0.07 diluted EPS); non-GAAP adjusted EPS $0.10.","Full year 2024 revenue $602.5M (-43.8%); net income $2.1M ($0.19 EPS).","Q1 2025 guidance: revenue $100-$120M, EPS loss $0.50 to $0.00 per share.","Cash & investments $162.3M, no debt; cites GLP-1 market headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":602463000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}